Last reviewed · How we verify
xifaxan
At a glance
| Generic name | xifaxan |
|---|---|
| Also known as | Rifaximin |
| Sponsor | Children's Hospital Los Angeles |
| Target | Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Approved indications
- Diarrhea due to E. Coli
- Hepatic encephalopathy
- Irritable bowel syndrome with diarrhea
Common side effects
Key clinical trials
- A Randomized, Prospective, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohn's Disease (Phase 2)
- Diarrhea-Predominant Irritable Bowel Syndrome in Persian Gulf Veterans (NA)
- The Clinical Effects of Nitazoxanide in Hepatic Encephalopathy Patients: A Pilot Study (Phase 2)
- Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleedin (Phase 4)
- Multicenter Double Blind Randomized Clinical Trial Assessing the Benefit of Adherent Invasive E. Coli Eradication in Adult Ileal and Ileo-colonic Crohn Disease (Phase 2)
- NCT02931123 (Phase 1)
- Rifaximin for Preventing Acute Graft Versus Host Disease (Phase 1)
- Effect of Enterococcus Faecium and Bacillus Subtilis-Containing Multispecies Probiotic Supplementation on the Therapeutic Efficacy of Rifaximin α in Patients With Small Intestinal Bacterial Overgrowth (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- xifaxan CI brief — competitive landscape report
- xifaxan updates RSS · CI watch RSS
- Children's Hospital Los Angeles portfolio CI